The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.47 as of 18 May 15:30
. The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Chandra Bhagat Pharma Ltd changed from 158.4 on March 2021 to 45.9 on March 2025 . This represents a CAGR of -21.94% over 5 years The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 196.47 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Chandra Bhagat Pharma Ltd changed from ₹ 29.88 crore on March 2021 to ₹ 39.48 crore on March 2025 . This represents a CAGR of 5.73% over 5 years The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Chandra Bhagat Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Bharat Immunological & Biological Corporation Ltd
The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets.
The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96.
The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.
About Chandra Bhagat Pharma Ltd
Chandra Bhagat Pharma Limited was incorporated as a Private Limited Company with the name 'Chandra Bhagat Pharma Private Limited' at Mumbai on March 10, 2003.
Consequent upon the conversion of the Company from Private Limited Company to Public Limited Company, the name of the Company was changed to 'Chandra Bhagat Pharma Limited' on March 20, 2019.
The Company incorporated in March, 2003 by Mr. Hemant Bhagat and Late.
Shree Chandravadan Bhagat.
On April 1, 2003, the Company acquired the going concern business of M/s.
Chandra Bhagat Corporation, partnership firm along with all its assets and liabilities.
FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Chandra Bhagat Pharma Ltd
Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Chandra Bhagat Pharma Ltd?
Market cap of Bharat Immunological & Biological Corporation Ltd is 75 Cr while Market cap of Chandra Bhagat Pharma Ltd is 24 Cr
What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Chandra Bhagat Pharma Ltd?
The stock performance of Bharat Immunological & Biological Corporation Ltd and Chandra Bhagat Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Chandra Bhagat Pharma Ltd?
As of May 18, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.47. On the other hand, Chandra Bhagat Pharma Ltd stock price is INR ₹33.0.
How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Chandra Bhagat Pharma Ltd compare?
To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Chandra Bhagat Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.